3,021 Shares in Quest Diagnostics Incorporated $DGX Acquired by Commerzbank Aktiengesellschaft FI

Commerzbank Aktiengesellschaft FI bought a new position in Quest Diagnostics Incorporated (NYSE:DGX) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 3,021 shares of the medical research company’s stock, valued at approximately $524,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. HB Wealth Management LLC raised its position in shares of Quest Diagnostics by 0.5% in the 4th quarter. HB Wealth Management LLC now owns 11,292 shares of the medical research company’s stock valued at $1,960,000 after acquiring an additional 58 shares during the period. Independent Advisor Alliance increased its holdings in shares of Quest Diagnostics by 1.4% in the third quarter. Independent Advisor Alliance now owns 4,232 shares of the medical research company’s stock worth $807,000 after acquiring an additional 59 shares in the last quarter. Ossiam increased its holdings in shares of Quest Diagnostics by 6.1% in the third quarter. Ossiam now owns 1,059 shares of the medical research company’s stock worth $202,000 after acquiring an additional 61 shares in the last quarter. Fulton Bank N.A. increased its holdings in shares of Quest Diagnostics by 1.7% in the fourth quarter. Fulton Bank N.A. now owns 4,180 shares of the medical research company’s stock worth $725,000 after acquiring an additional 68 shares in the last quarter. Finally, Checchi Capital Advisers LLC increased its holdings in shares of Quest Diagnostics by 5.6% in the fourth quarter. Checchi Capital Advisers LLC now owns 1,326 shares of the medical research company’s stock worth $230,000 after acquiring an additional 70 shares in the last quarter. 88.06% of the stock is currently owned by institutional investors.

Quest Diagnostics Stock Down 0.8%

Quest Diagnostics stock opened at $186.52 on Friday. The company has a quick ratio of 1.08, a current ratio of 1.18 and a debt-to-equity ratio of 0.67. Quest Diagnostics Incorporated has a twelve month low of $164.65 and a twelve month high of $213.50. The stock has a market capitalization of $20.65 billion, a PE ratio of 20.61, a price-to-earnings-growth ratio of 2.22 and a beta of 0.60. The company has a 50 day moving average of $195.72 and a 200-day moving average of $189.92.

Quest Diagnostics (NYSE:DGX) last posted its quarterly earnings data on Tuesday, April 21st. The medical research company reported $2.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.37 by $0.13. Quest Diagnostics had a net margin of 9.07% and a return on equity of 15.60%. The company had revenue of $2.90 billion for the quarter, compared to the consensus estimate of $2.83 billion. During the same period last year, the company earned $1.94 earnings per share. The firm’s revenue was up 9.2% compared to the same quarter last year. Quest Diagnostics has set its FY 2026 guidance at 10.630-10.830 EPS. On average, equities research analysts anticipate that Quest Diagnostics Incorporated will post 10.72 EPS for the current fiscal year.

Quest Diagnostics announced that its board has initiated a share buyback plan on Tuesday, February 10th that allows the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization allows the medical research company to purchase up to 4.7% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s leadership believes its shares are undervalued.

Insider Buying and Selling at Quest Diagnostics

In other news, SVP Michael E. Prevoznik sold 3,878 shares of Quest Diagnostics stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $206.21, for a total value of $799,682.38. Following the sale, the senior vice president directly owned 37,557 shares in the company, valued at $7,744,628.97. This trade represents a 9.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Karthik Kuppusamy sold 2,628 shares of Quest Diagnostics stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $204.86, for a total transaction of $538,372.08. Following the completion of the sale, the senior vice president owned 13,441 shares in the company, valued at $2,753,523.26. This trade represents a 16.35% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 18,421 shares of company stock valued at $3,790,214 over the last ninety days. 0.88% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

DGX has been the subject of several recent analyst reports. Mizuho increased their price target on Quest Diagnostics from $210.00 to $235.00 and gave the stock an “outperform” rating in a report on Thursday, February 12th. Barclays upped their price target on shares of Quest Diagnostics from $225.00 to $230.00 and gave the company an “overweight” rating in a report on Wednesday, April 22nd. UBS Group upped their price target on shares of Quest Diagnostics from $210.00 to $220.00 and gave the company a “neutral” rating in a report on Wednesday, April 22nd. Weiss Ratings upgraded shares of Quest Diagnostics from a “buy (b)” rating to a “buy (b+)” rating in a report on Monday, May 4th. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $225.00 price target on shares of Quest Diagnostics in a report on Tuesday, April 21st. Seven equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. According to MarketBeat, Quest Diagnostics has an average rating of “Moderate Buy” and a consensus price target of $216.58.

Key Headlines Impacting Quest Diagnostics

Here are the key news stories impacting Quest Diagnostics this week:

• Positive Sentiment: Zacks Research raised FY2026, FY2027, and Q3 2027 EPS estimates for Quest Diagnostics, signaling improved earnings expectations.
• Positive Sentiment: Barron’s highlighted Quest Diagnostics as one of the stocks potentially rebounding after a rough patch, which may support investor interest. Quest Diagnostics, Altria, and 12 More Stocks That Are Coming Back to Life After a Rough Patch
• Neutral Sentiment: A new valuation-focused article examined Quest Diagnostics’ investment narrative, but it did not include a direct corporate catalyst. How The Investment Narrative For Quest Diagnostics (DGX) Is Shifting With New Valuation Work
• Negative Sentiment: Zacks Research cut estimates for Q2 2026, Q2 2027, Q1 2028, and FY2028 EPS, which could pressure sentiment if investors focus on slower longer-term earnings growth.

Quest Diagnostics Company Profile

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.